Payment overview · 2025
General Payments
$1,179.35
42 reported records · 16 companies
Healthcare provider profile · identity verified
Lisa Ann Dructor, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · VOORHEES, NJ · NPI 1245296169
Verified facts
What the public records show
CMS Open Payments records show Lisa Ann Dructor, D.O. received $1,179.35 in general payments during 2025 across 42 reported records.
Cook Medical LLC accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Mounjaro, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cook Medical LLC | Unresolved — no canonical attribution shown | $407.49 | 34.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.94 | 12.2% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $99.77 | 8.5% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $91.70 | 7.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.87 | 6.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $68.96 | 5.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.11 | 5.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.46 | 4.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.10 | 3.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.53 | 2.5% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $27.45 | 2.3% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.32 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.74 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.52 | 1.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.82 | 1.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.57 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $863.85 | 40 |
| Travel and Lodging | $255.50 | 1 |
| Education | $60.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $407.49 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $99.77 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $98.62 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $95.86 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $81.70 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.87 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $68.96 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.11 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.11 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.46 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.46 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.10 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $27.45 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
40 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
114 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 974 | 297 |
| Eliquis | Apixaban | 704 | 162 |
| Furosemide | Furosemide | 579 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 536 | 171 |
| Metoprolol Succinate | Metoprolol Succinate | 420 | 151 |
| Gabapentin | Gabapentin | 417 | 131 |
| Potassium Chloride | Potassium Chloride | 406 | 110 |
| Metoprolol Tartrate | Metoprolol Tartrate | 392 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 383 | 180 |
| Losartan Potassium | Losartan Potassium | 332 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 326 | 110 |
| Omeprazole | Omeprazole | 276 | 77 |
| Metformin Hcl | Metformin Hcl | 273 | 70 |
| Mirtazapine | Mirtazapine | 273 | 84 |
| Hydralazine Hcl | Hydralazine Hcl | 262 | 88 |
| Lisinopril | Lisinopril | 262 | 92 |
| Famotidine | Famotidine | 257 | 96 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 249 | 29 |
| Trazodone Hcl | Trazodone Hcl | 237 | 65 |
| Sertraline Hcl | Sertraline Hcl | 236 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 224 | 49 |
| Carvedilol | Carvedilol | 216 | 92 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 73 |
| Quetiapine Fumarate | Quetiapine Fumarate | 202 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 112 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 97 |
| Latanoprost | Latanoprost | 144 | 41 |
| Montelukast Sodium | Montelukast Sodium | 136 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 65 |
| Buspirone Hcl | Buspirone Hcl | 130 | 36 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 126 | 94 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 118 | 88 |
| Donepezil Hcl | Donepezil Hcl | 118 | 43 |
| Levetiracetam | Levetiracetam | 118 | 37 |
| Divalproex Sodium | Divalproex Sodium | 117 | 15 |
| Finasteride | Finasteride | 117 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 114 | 31 |
| Divalproex Sodium Er | Divalproex Sodium | 112 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 111 | 79 |
| Xarelto | Rivaroxaban | 111 | 39 |
| Baclofen | Baclofen | 104 | 24 |
| Risperidone | Risperidone | 100 | 13 |
| Simvastatin | Simvastatin | 99 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 41 |
| Prednisone | Prednisone | 89 | 45 |
| Sucralfate | Sucralfate | 89 | 22 |
| Jardiance | Empagliflozin | 88 | 21 |
| Allopurinol | Allopurinol | 85 | 46 |
| Memantine Hcl | Memantine Hcl | 82 | 26 |
| Nystatin | Nystatin | 79 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 30 |
| Albuterol Sulfate | Albuterol Sulfate | 69 | 55 |
| Aripiprazole | Aripiprazole | 64 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 62 | 20 |
| Ezetimibe | Ezetimibe | 61 | 27 |
| Ozempic | Semaglutide | 61 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 60 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 23 |
| Spironolactone | Spironolactone | 57 | 33 |
| Bupropion Xl | Bupropion Hcl | 55 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 25 |
| Tradjenta | Linagliptin | 52 | suppressed |
| Enulose | Lactulose | 50 | 17 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 50 | 19 |
| Olanzapine | Olanzapine | 49 | 12 |
| Topiramate | Topiramate | 49 | 15 |
| Ammonium Lactate | Ammonium Lactate | 47 | 30 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 47 | 47 |
| Torsemide | Torsemide | 47 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 19 |
| Meloxicam | Meloxicam | 46 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 36 |
| Valsartan | Valsartan | 44 | 26 |
| Benztropine Mesylate | Benztropine Mesylate | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 23 |
| Meclizine Hcl | Meclizine Hcl | 42 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 12 |
| Bumetanide | Bumetanide | 40 | 22 |
| Myrbetriq | Mirabegron | 40 | 19 |
| Alprazolam | Alprazolam | 39 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 26 |
| Nifedipine Er | Nifedipine | 38 | 22 |
| Midodrine Hcl | Midodrine Hcl | 36 | 22 |
| Novolog Flexpen | Insulin Aspart | 36 | 20 |
| Pregabalin | Pregabalin | 36 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 19 |
| Mupirocin | Mupirocin | 34 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 21 |
| Anastrozole | Anastrozole | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | 14 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 32 | 13 |
| Ibuprofen | Ibuprofen | 32 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 27 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 22 |
| Gemtesa | Vibegron | 31 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 31 | 22 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 13 |
| Alendronate Sodium | Alendronate Sodium | 30 | 17 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 30 | 17 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Budesonide | Budesonide | 29 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 22 |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 18 |
| Enoxaparin Sodium | Enoxaparin Sodium | 28 | 18 |
| Glimepiride | Glimepiride | 27 | 14 |
| Ketoconazole | Ketoconazole | 27 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | 16 |
| Glipizide | Glipizide | 26 | 16 |
| Dexamethasone | Dexamethasone | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 16 |
| Nitroglycerin | Nitroglycerin | 25 | 24 |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Digoxin | Digoxin | 24 | 13 |
| Naproxen | Naproxen | 24 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 24 | 15 |
| Atenolol | Atenolol | 23 | 13 |
| Bicalutamide | Bicalutamide | 23 | suppressed |
| Cabergoline | Cabergoline | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | 14 |
| Cyclosporine | Cyclosporine | 23 | 11 |
| Hydrocortisone | Hydrocortisone | 23 | 18 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 23 | 16 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 14 |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | 20 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | 14 |
| Cephalexin | Cephalexin | 20 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Nyamyc | Nystatin | 20 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Azelastine Hcl | Azelastine Hcl | 19 | 12 |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | 14 |
| Cefdinir | Cefdinir | 18 | 12 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Restasis | Cyclosporine | 18 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Colchicine | Colchicine | 16 | 14 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lactulose | Lactulose | 15 | 12 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | 11 |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Acetic Acid | Acetic Acid | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Daptomycin | Daptomycin | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | 11 |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,179.35 · 42 records | Cook Medical LLC | ACCRUFER, AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, FARXIGA, GEMTESA, KISUNLA, Kerendia, MOUNJARO, NUZYRA, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, Veozah, XIFAXAN, ZENITH SPIRAL-Z, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error